PCVX Stock Analysis: Buy, Sell, or Hold?
PCVX - Vaxcyte, Inc. Common Stock
$52.99
0.88 (1.68%)
▲
5d:
+6.91%
30d:
+11.81%
90d:
-5.28%
BUY
MODERATE Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When PCVX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: PCVX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: PCVX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: PCVX is currently trading at $52.98, which is considered extended relative to its 30-day fair value range of $46.92 to $51.12.
Technical Outlook: Technically, PCVX is in a downtrend. The price is approaching resistance at $53.48. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PCVX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $109.00 (+109.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PCVX is in a downtrend. The price is approaching resistance at $53.48. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PCVX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $109.00 (+109.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$46.92 -
$51.12
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 109.2% below Wall St target ($109.00)
Trading Range Analysis
30-Day Trading Range
$46.92 -
$51.12
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$45.30
Resistance Level
$53.48
Current Trend
Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.02
Wall Street Target
$109.00
(+109.2%)
Share & Embed Analysis
Last updated: June 23, 2026 1:29 PM ET
Data refreshes hourly during market hours. Next update: 2:29 PM
Data refreshes hourly during market hours. Next update: 2:29 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PCVX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Elvia Cowan
SELL
3000 shares
2026-04-07
Elvia Cowan
SELL
1892 shares
2026-03-17
Elvia Cowan
SELL
2500 shares
2026-03-11
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 67 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$105 | 66 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 59 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 67 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 64 BUY |
